Castration-Resistant Prostatic Cancer
Conditions
Brief summary
A study evaluating the safety, preliminary efficacy and pharmacokinetics of ipatasertib in combination with atezolizumab and docetaxel in participants with mCRPC previously treated with second-generation AR (Androgen Receptor)-targeted therapy. The study consists of two parts: \[1\] Part A: Safety run-in cohort of approximately 12 participants; \[2\] Part B: Expansion cohort of approximately 38 participants. All participants in this study will continue to be treated until progression of disease, loss of clinical benefit, unacceptable toxicity or withdrawal of consent.
Interventions
DRUGIpatasertib
Ipatasertib will be administered at a dose of 400 mg, as per the dosing schedule described above.
DRUGAtezolizumab
Atezolizumab will be administered at a fixed dose of 1200 mg, as per the dosing schedule described above.
DRUGDocetaxel
Docetaxel will be administered at a dose of 75 mg/m\^2, as per the dosing schedule described above.
Sponsors
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Ability to comply with the study protocol. * Adenocarcinoma of the prostate without small-cell or neuroendocrine features. * Metastatic disease that cannot be treated with curative intent. * Surgical or medical castration with testosterone serum level \< 50 ng/dL (1.7 nM). * For participants treated with luteinizing hormone-releasing hormone analogs, initiation therapy \>= 4 weeks prior to the first dose of study treatment and continued therapy throughout study treatment. * Progression of Prostate Cancer. * Receipt of at least one prior line of second generation AR-targeted therapy. * For participants in Part A of study: measurable visceral disease or measurable extrapelvic adenopathy per RECIST v1.1. * For participants in Part B of study: either measurable visceral disease or measurable extrapelvic adenopathy by RECIST v1.1 or bone lesions by bone scan, or both. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Life expectancy of \>= 3 months. * Ability to swallow oral study drug. * Adequate organ and bone marrow function. * Resolved or stabilized toxicities resulting from previous therapy to Grade 1 (except for alopecia and neuropathy). * For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm.
Exclusion criteria
* Prior treatment with an AKT, PI3K, or mTOR inhibitor. * Prior treatment with radium or other therapeutic radiopharmaceuticals for prostate cancer. * Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137). * Prior treatment with docetaxel or another chemotherapy agent for mCRPC. * Treatment with investigational therapy within 14 days prior to initiation of study drug. * History or known presence of central nervous system metastases including leptomeningeal carcinomatosis. * Uncontrolled tumor-related pain. * Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrollment. * Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord compression) should be considered for loco- regional therapy if appropriate prior to enrollment. * Non-study-related minor surgical procedures =\< 5 days or major (invasive) surgical procedure =\< 28 days prior to the first dose of study treatment. * Active Hepatitis B and C infection (HBV/HCV). * Known HIV infection. * Uncontrolled pleural effusion, pericardial effusion, or ascites. * Illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment. * Malabsorption syndrome or other condition that would interfere with enteral absorption. * Serious infection requiring antibiotics within 14 days prior to the first dose of study treatment. * Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study. * History of another malignancy within 5 years prior to enrollment. * History of clinically significant cardiovascular dysfunction. * Presence of any other condition, metabolic dysfunction, physical examination finding, or laboratory finding that may increase the risk associated with study participation or may interfere with the interpretation of study results and in the opinion of the investigator, would make the participant inappropriate for study entry. Ipatasertib-Specific
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants with Adverse Events (AEs) | Up to 35 months | Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) |
| Confirmed Prostate Specific Antigen (PSA) Response | Up to 35 months | Defined as the proportion of participants with a reduction in their PSA levels of 50% or more from baseline, confirmed by a second evaluation at least 3 weeks later |
| Overall Response Rate (ORR) (In participants presenting with measurable visceral disease or measurable extrapelvic adenopathy at baseline) | Up to 35 months | Defined as the proportion of participants with a complete response (CR) or partial response (PR) on two consecutive occasions \>= 4 weeks apart, as determined by the Investigator according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumors, Version 1.1) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Documented Objective Response (DOR) (In participants presenting with measurable visceral disease or measurable extrapelvic adenopathy at baseline) | Up to 35 months | Defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1 |
| Clinical Benefit Rate (CBR) (In participants presenting with measurable visceral disease or measurable extrapelvic adenopathy at baseline) | Up to 35 months | Defined as the proportion of participants who have an objective response (a CR or a PR) or stable disease for at least 27 weeks, as determined by the Investigator according to RECIST v1.1 and PCWG3 criteria |
| Time to PSA Progression | Up to 35 months | — |
| Serum Concentrations (ng/mL) of Atezolizumab at pre-specified timepoints | Up to 35 months | — |
| Percentage of Participants with Anti-Drug Antibodies (ADAs) to Atezolizumab | Up to 35 months | — |
| Plasma Concentrations (ng/mL) of Ipatasertib and G-037720 at pre-specified timepoints | Up to 35 months | — |
| radiographic Progression-Free Survival (rPFS) | Up to 35 months | Assessed according to the Prostate Cancer Working Group 3 (PCWG3) criteria |
| Overall Survival (OS) (median OS and landmark survival at 12, 18 and 24 months) | Up to 35 months | — |
Countries
France, Italy, Spain, Switzerland
Outcome results
None listed